Journal
BIOMARKERS IN MEDICINE
Volume 2, Issue 4, Pages 363-384Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/17520363.2.4.363
Keywords
Alzheimer's disease; biomarker; microtubule-associated Tau protein; neurofibrillary degeneration; phosphorylation; tauopathies
Categories
Funding
- Inserm
- GVRS
- IMPRT Region Nord/Pas-de-Calais
- FEDER
- AFM [13510, 12570]
- ANR [ANR-05-BLANC-0320-01]
- European Community
- cNEUPRO
- MEMOSAD [2006121]
Ask authors/readers for more resources
The microtubule-associated protein Tau is mainly expressed in neurons of the CNS and is crucial in axonal maintenance and axonal transport. The rationale for Tau as a biomarker of neurodegenerative diseases is that it is a major component of abnormal intraneuronal aggregates observed in numerous tauopathies, including Alzheimer's disease. The molecular diversity of Tau is very useful when analyzing it in the brain or in the peripheral fluids. Immunohistochemical and biochemical characterization of Tau aggregates in the brain allows the postmortem classification and differential diagnosis of tauopathies. As peripheral biomarkers of Alzheimer's disease in the cerebrospinal fluid, Tau proteins are now validated for diagnosis and predictive purposes. For the future, the detailed characterization of Tau in the brain and in peripheral fluids will lead to novel promising biomarkers for differential diagnosis of dementia and monitoring of therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available